Maram Morizeq ALKHAMMASH, Bussma Ahmed BUGİS

A COMPARISON REVIEW OF THE CLINICAL HEALTHCARE SERVICES PROVIDED TO LIVER DISEASE PATIENTS IN THE GCC

Liver diseases are a critical health concern in the Gulf Cooperation Council (GCC). Fatty liver disease andviral hepatitis are the two most common liver-disease-related health problems in the region. Hepatocellularcarcinoma development adds to the burden of liver cirrhosis. Given the importance of identifying patientswith liver disease, it is essential to examine the GCC’s healthcare services. The goal of this study was tocompare the clinical care services provided to liver disease patients in GCC member countries. Asystematic comparative analysis of GCC studies from 2014 to 2020 on related topics was conducted.Articles relevant to liver disease prevalence rate, incidence, and clinical healthcare services, includingmental health support, palliative care, liver surgery and transplantation, management of viral hepatitis Band C, dental care services, HBV and pregnancy, vaccination among HCWs and national screening wereincluded in this study. The study results showed that most of the clinical healthcare services provided toliver disease patients are available in all GCC member countries. The prevalence of communicablediseases has significantly decreased among the GCC countries, indicating that there are successfulhealthcare systems for tracking and controlling disease spread at the level of the GCC. The same can besaid of the management of viral hepatitis in Gulf countries. Despite the similarities of clinical servicesprovided to liver disease patients, the study concluded that there were differences in the availability of livertransplantation programs and the level of palliative care among GCC member countries.

PDF

___

1. World Health Organization. Health systems strengthening glossary; 2011. https://www.who.int/healthsystems/hss_glossar y/en/index5.html
2. Johnson J, Stoskopf C, Shi L. Comparative Health Systems: A Global Perspective. 2nd ed. Burlington, MA: Jones & Bartlett Learning; 2018.
3. Riegelman R, Kirkwood B. Public health 101: Improving community health. 3rd ed. Burlington, MA: Jones & Bartlett Learning; 2019.
4. Asrani S, Devarbhavi H, Eaton J, et al. Burden of liver diseases in the world. J Hepatol. 2019;70(1):151-171.
5. Fayadh M. 40 years observation in liver diseases in the Middle East., J Liver. 2016;5(3):48.
6. Younossi Z, Koenig A, Abdelatif D, et al. Wymer M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64(1):73-84.
7. Szanto K, Li J, Cordero P, et al. Ethnic differences and heterogeneity in genetic and metabolic makeup contributing to nonalcoholic fatty liver disease. Diabetes Metab Syndr Obes. 2019;12:357-367.
8. Al Hammadi H, Reilly J. Prevalence of obesity among school-age children and adolescents in the Gulf cooperation council (GCC) states: a systematic review. BMC Obes. 2019,6:3.
9. Alswat K, Aljumah AA, Sanai FM, et al. Nonalcoholic fatty liver disease burden – Saudi Arabia and United Arab Emirates, 2017–2030. Saudi J Gastroenterol. 2018;24(4):211-219.
10. Ringelhan M, O'Connor T, Protzer U, et al. The direct and indirect roles of HBV in liver cancer: prospective markers for HCC screening and potential therapeutic targets. J Pathol. 2015;235(2):355-367.
11. Alavian SM, Haghbin H. Relative Importance of Hepatitis B and C Viruses in Hepatocellular Carcinoma in EMRO Countries and the Middle East: A Systematic Review. Hepat Mon. 2016;16(3):e35106.
12. Sanai FM, Alghamdi H, Alswat KA, et al. Greater prevalence of comorbidities with increasing age: Cross-sectional analysis of chronic hepatitis B patients in Saudi Arabia. Saudi J Gastroenterol. 2019;25(3):194-200.
13. Messina JP, Humphreys I, Flaxman A, et al. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology. 2015;61(1):77-87.
14. Aljumah AA, Abaalkhail F, Al-Ashgar H, et al. Epidemiology, disease burden, and treatment strategies of chronic hepatitis C virus infections in Saudi Arabia in the new treatment paradigm shift. Saudi J Gastroenterol. 2016;22(4):269- 281.
15. Gutierrez JA, Lawitz EJ, Poordad F. Interferonfree, direct-acting antiviral therapy for chronic hepatitis C. J Viral Hepat. 2015;22(11):861-870.
16. Mohamoud YA, Riome S, Abu-Raddad LJ. Epidemiology of hepatitis C virus in the Arabian Gulf countries: Systematic review and metaanalysis of prevalence. Int J Infect Dis. 2016; 46: 116-125.
17. Dutta A, Dubey A. Detection of Liver Cancer using Image Processing Techniques. 2019 International Conference on Communication and Signal Processing (ICCSP). 2019;315-318.
18. Alqahtani A, Khan Z, Alloghbi A, et al. Hepatocellular Carcinoma: Molecular Mechanisms and Targeted Therapies. Medicina (Kaunas). 2019;55(9):526.
19. Dimitroulis D, Damaskos C, Valsami S, et al. From diagnosis to treatment of hepatocellular carcinoma: An epidemic problem for both developed and developing world. World J Gastroenterol. 2017;23(29):5282-5294.
20. Cancer Incidence Report Saudi Arabia 2014. Saudi Health Council Saudi Cancer Registry; 2014. https://nhic.gov.sa/eServices/Documents/2014. pdf.
21. Global Cancer Observatory. International Agency for Research on Cancer; 2020. https://gco.iarc.fr/.
22. Alghamdi IG, Alghamdi MS. The Incidence Rate of Liver Cancer in Saudi Arabia: An Observational Descriptive Epidemiological Analysis of Data from the Saudi Cancer Registry (2004–2014). Cancer Manag Res. 2020; 12:1101-1111.
23. Sharafi H, Alavian SM. The Rising Threat of Hepatocellular Carcinoma in the Middle East and North Africa Region: Results From Global Burden of Disease Study 2017. Clin Liver Dis. 2020;14(6):219-223.
24. Mokdad AA, Singal AG, Yopp AC. Treatment of Liver Cancer. JAMA. 2016;315(1):100.
25. Liu CY, Chen KF, Chen PJ. Treatment of Liver Cancer. Cold Spring Harb Perspect Med. 2015;5(9):a021535.
26. Gosadi IM. National screening programs in Saudi Arabia: Overview, outcomes, and effectiveness. J Infect Public Health. 2019;12(5):608-614.
27. Abdo AA, Sanai FM, Al-Faleh FZ. Epidemiology of viral hepatitis in Saudi Arabia: are we off the hook? Saudi J Gastroenterol. 2012;18(6):349- 357.
28. Hegazy A, Albar HM, Albar NH. Hepatitis B Vaccination Coverage and Knowledge Among Healthcare Workers at a Tertiary Hospital in Jeddah, Saudi Arabia. J Adv Med Pharm Sci. 2016;11(1):1-9
29. Khalil H. Willingness of Saudi dental professionals to treat Hepatitis B virus-infected patients. Niger J Clin Pract. 2015;18(2):247-250.
30. Abaalkhail F, Elsiesy H, AlOmair A, et al. SASLT practice guidelines for the management of hepatitis B virus. Saudi J Gastroenterol. 2014;20(1):5-25.
31. Al Sebayel M, Abaalkhail F, Al Abbad S, et al. Liver transplantation in the Kingdom of Saudi Arabia. Liver Transpl. 2017;23(10):1312-1317.
32. Al-Zahrani O, Eldali A, Al-Shahri MZ. Prevalence and severity of pain in cancer patients in an outpatient palliative care setting in Saudi Arabia. Qatar Med J. 2014;2014(1):38-45.
33. Al Zaabi M, Al Quraishi H, Al Rifai A, et al. Hepatitis B Care Pathway in the United Arab Emirates: Current Situation, Gaps, and Actions. Eur Med J Hepatol. 2019.
34. Khalaf H, Marwan I, Al-Sebayel M, et al. Status of liver transplantation in the Arab world. Transplantation. 2014;97(7):722-724.
35. Al Romaihi HE, Ganesan N, Farag EA, et al. Demographics and Epidemiology of Hepatitis B in the State of Qatar: A Five-Year SurveillanceBased Incidence Study. Pathogens. 2019;8(2):68.
36. Al-Romaihi H, Al-Masri H, Shawky S, at el. Assessment of hepatitis B immunization programme among school students in Qatar. East Mediterr Health J. 2018;24(8):736–744.
37. Guanche Garcell H, Villanueva Arias A, Guilarte García E, et al. Seroprotection against VaccinePreventable Diseases amongst Health Care Workers in a Community Hospital, Qatar. Int J Occup Environ Med. 2016;7(4):234-240.
38. Ayman A, Azza AH, Yasser K, et al. The Role of Palliative Care in the Management of Patients with Advanced Hepatocellular Carcinoma: A Single Institution Experience. , J Pat Care. 2016; 2(2):1000112.
39. Janahi EM. Prevalence and Risk Factors of Hepatitis B Virus Infection in Bahrain, 2000 through 2010. PloS One, 2014; 9(2): e87599.
40. Maaroufi, A, Vince, A, Himatt, SM, et al. Historical epidemiology of hepatitis C virus in select countries - volume 4. J Viral Hepat. 2017;24(Suppl. 2):8-24.
41. Al-Saleh K, Al-Awadi A, Soliman NA, et al. Timing and Outcome of Referral to the First Stand-Alone Palliative Care Center in the Eastern Mediterranean Region, the Palliative Care Center of Kuwait. Am J Hosp Palliat Care. 2017;34(4):325-329.
42. Al Baqlani SA, Sy BT, Ratsch BA, et al. Molecular Epidemiology and Genotyping of Hepatitis B Virus of HBsAg-Positive Patients in Oman. PLoS One. 2014;9(5):e97759.
43. Fadhil I, Lyons G, Payne S. Barriers to, and opportunities for, palliative care development in the Eastern Mediterranean Region. Lancet Oncol. 2017;18(3):e176-e184.
44. Blach S, Sanai FM. HCV Burden and Barriers to Elimination in the Middle East. Clin Liver Dis (Hoboken). 2019;14(6):224-227.
45. Al Awaidy ST, Ezzikouri S. Moving towards hepatitis B elimination in Gulf Health Council states: From commitment to action. J Infect Public Health. 2020;13(2):221-227.